Insider Buying: Alumis Inc. (NASDAQ:ALMS) Director Buys 16,104 Shares of Stock

Alumis Inc. (NASDAQ:ALMS) Director Alan Colowick acquired 16,104 shares of the firm’s stock in a transaction that occurred on Tuesday, April 1st. The stock was purchased at an average cost of $6.97 per share, with a total value of $112,244.88. Following the purchase, the director now directly owns 16,104 shares in the company, valued at approximately $112,244.88. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Alumis Stock Performance

NASDAQ ALMS traded down $1.30 on Thursday, reaching $8.54. The stock had a trading volume of 595,988 shares, compared to its average volume of 307,069. Alumis Inc. has a 1 year low of $3.18 and a 1 year high of $13.53. The business has a 50 day moving average price of $5.42 and a 200 day moving average price of $8.24.

Analyst Ratings Changes

ALMS has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Alumis in a research report on Wednesday, March 26th. Cantor Fitzgerald restated an “overweight” rating on shares of Alumis in a research report on Thursday, March 20th. Finally, Oppenheimer started coverage on Alumis in a report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 target price on the stock. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Alumis presently has an average rating of “Buy” and an average price target of $26.00.

Institutional Investors Weigh In On Alumis

Several large investors have recently made changes to their positions in the company. Tang Capital Management LLC grew its position in Alumis by 40.6% in the fourth quarter. Tang Capital Management LLC now owns 600,000 shares of the company’s stock worth $4,716,000 after acquiring an additional 173,406 shares in the last quarter. Foresite Capital Management V LLC raised its holdings in Alumis by 3.5% during the fourth quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company’s stock valued at $45,426,000 after buying an additional 194,459 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of Alumis by 1,257.0% in the fourth quarter. BNP Paribas Financial Markets now owns 34,835 shares of the company’s stock worth $274,000 after buying an additional 32,268 shares during the last quarter. Ally Bridge Group NY LLC boosted its stake in shares of Alumis by 6.4% during the 4th quarter. Ally Bridge Group NY LLC now owns 445,259 shares of the company’s stock worth $3,500,000 after acquiring an additional 26,843 shares in the last quarter. Finally, Foresite Capital Management VI LLC acquired a new stake in Alumis in the 4th quarter worth approximately $33,033,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.